The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting

R. Stephens, N. H. Gower, V. Napp, R. M. Rudd, S. G. Spiro, H. Thorpe (London, United Kingdom)

Source: Annual Congress 2002 - Lung cancer: treatment
Session: Lung cancer: treatment
Session type: Oral Presentation
Number: 2534
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Stephens, N. H. Gower, V. Napp, R. M. Rudd, S. G. Spiro, H. Thorpe (London, United Kingdom). The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Eur Respir J 2002; 20: Suppl. 38, 2534

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018




The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007


Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial
Source: Eur Respir J 2007; 30: Suppl. 51, 240s
Year: 2007

A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics
Source: Eur Respir J 2001; 18: Suppl. 33, 319s
Year: 2001

Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008


A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario
Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Year: 2011


Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005


Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011


Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 241s
Year: 2007

Bevacizumab as first line treatment for advanced non-small cell lung cancer (NSCLC): a meta-analysis of randomised placebo-controlled trials (RCTs)
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008



Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007


Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003


Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017




Short-time exercise-induced rehabilitation in non-small cell lung cancer patients during in-hospital chemotherapy treatment: a randomized controlled trial
Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care
Year: 2017